FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
34.32 USD
1.6 (4.66%)
Balance Sheet
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Total Cash
228.63M
234.31M
323.12M
353.46M
467.19M
794.44M
1.17B
1.73B
2.55B
3.77B
Total Cash %
143.13
76.71
73.79
60.73
65.37
75.32
75.32
75.32
75.32
Receivables
22.18M
34.84M
54.74M
74.14M
83.03M
131.1M
193.47M
285.5M
421.32M
621.75M
Receivables %
13.88
11.41
12.5
12.74
11.62
12.43
12.43
12.43
12.43
Inventories
3.82M
4.43M
4.3M
5.36M
7.2M
14.25M
21.03M
31.03M
45.79M
67.57M
Inventories %
2.39
1.45
0.98
0.92
1.01
1.35
1.35
1.35
1.35
Payable
2.56M
1M
3.79M
17.73M
13.74M
16.37M
24.16M
35.66M
52.62M
77.65M
Payable %
1.6
0.33
0.86
3.05
1.92
1.55
1.55
1.55
1.55
Cap Ex
-2M
-100.3M
-40.17M
-312k
-1.15M
-91.72M
-135.35M
-199.75M
-294.77M
-435M
Cap Ex %
-1.25
-32.84
-9.17
-0.05
-0.16
-8.7
-8.7
-8.7
-8.7
